Back to Search
Start Over
Table S3 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Baseline gene expression analysis of B cell lymphoma cell lines with higher (IC50 < 200 nM) or lower sensitive (IC50 > 400 nM) to PQR309.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....5d5ffa2486f6bf0e9326638aa0444de9
- Full Text :
- https://doi.org/10.1158/1078-0432.22463267.v1